Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Gross Profit | -15M | 4.3% |
Cost of Revenue | 15M | 1.5% |
Operating expense | 61M | 15.7% |
Net Income | -56M | 19% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 484M | 7.3% |
Total Liabilities | 91M | 8% |
Total Equity | 393M | 10.2% |
Shares Outstanding | 60M | 0.2% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | -45M | 49.6% |
Cash from investing | 11M | 82% |
Cash from financing | 680,000 | 96.9% |
EPS
Financial Highlights for Pliant Therapeutics in Q2 '24
Gross Profit stood at -15M, marking a 4.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 15M, a -1.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 61M, showing a 15.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -56M, showing a -19% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Pliant Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.